{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["xaluritamig"]],"indication":"metastatic castration-resistant prostate cancer previously treated with chemotherapy","name":"XALute","nct_id":"NCT06691984","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=xalute-nct06691984. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants with metastatic castration-resistant prostate cancer (mCRPC) will be randomized to receive Xaluritamig as an intravenous (IV) infusion.","label":"Xaluritamig","type":"EXPERIMENTAL"},{"description":"Participants with mCRPC will be randomized to receive cabazitaxel as an IV infusion, or a second androgen receptor-directed therapy of either abiraterone as oral tablets, or enzalutamide as oral tablets at the investigator's discretion.","label":"Cabazitaxel/Abiraterone/Enzalutamide","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2029-07-30","type":"ESTIMATED"},"conditions":["Metastatic Castration-resistant Prostate Cancer"],"enrollment":{"count":707,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Xaluritamig","otherNames":[],"type":"DRUG"},{"name":"Abiraterone","otherNames":[],"type":"DRUG"},{"name":"Enzalutamide","otherNames":[],"type":"DRUG"},{"name":"Cabazitaxel","otherNames":[],"type":"DRUG"}],"last_update":"2026-05-15","lead_sponsor":"Amgen","official_title":"A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Chemotherapy","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2029-01-02","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall Survival (OS)","timeFrame":"Up to approximately 53 months"}],"references":[],"start_date":{"date":"2024-12-09","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)","url":"https://clinicaltrials.gov/study/NCT06691984"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/xalute-nct06691984"}